Hemispherx Biopharma, Inc.

Company Listings from SPi: Hemispherx Biopharma, Inc.

You are here: Home >> SPi Company Listings >> Hemispherx Biopharma, Inc.

 

Hemispherx Biopharma, Inc.

Website:
http://

Search for other references to "hemispherx" on SPi News

Latest Hemispherx Biopharma, Inc. News

CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from ope...... 19:19 GMT Wednesday 16th May 2018

Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders t...... 13:30 GMT Wednesday 16th May 2018

Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum ORLANDO, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB) announced today that it will be presenting at the 4 Annual Immuno-Oncology: BD&L and Investment Forum on Frida...... 13:30 GMT Monday 14th May 2018

Hemispherx to Present at the 8th Annual LD Micro Invitational ORLANDO, Fla., May 10, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB) announced today that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 11:00...... 13:30 GMT Thursday 10th May 2018

Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinical Trials ORLANDO, Fla., May 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) would like to share a letter with its stockholders today, highlighting 2017 results...... 13:30 GMT Wednesday 2nd May 2018

Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market ORLANDO, Fla., April 20, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) (“Hemispherx” or the “Company”), a research and development and emerging...... 14:28 GMT Friday 20th April 2018

Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs ORLANDO, Fla., April 17, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, i...... 13:30 GMT Tuesday 17th April 2018

Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients ORLANDO, Fla., April 04, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB), focused on pharmaceutical research, said it amended its agreement with Netherlands-based myTomorrows to inc...... 13:30 GMT Wednesday 4th April 2018

Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017 ORLANDO, Fla., April 02, 2018 (GLOBE NEWSWIRE) -- (NYSE American:HEB), focused on immuno-pharmaceutical research and the commercial development of its immunology products Amplige...... 13:30 GMT Monday 2nd April 2018

Hemispherx Biopharma and UNMC Partner to Take on Pancreatic Cancer ORLANDO, Fla., March 14, 2018 (GLOBE NEWSWIRE) -- The University of Nebraska Medical Center and Hemispherx Biopharma, Inc. (NYSE American:HEB) are joining forces to take on pancr...... 12:30 GMT Wednesday 14th March 2018

Buy Hemispherx Biopharma, Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers